Key Points from the 8-K Filing

• On March 30, 2026, Telomir Pharmaceuticals, Inc. (“the Company”) received a letter from Nasdaq Capital Markets.
• The letter confirmed that the Company is now in compliance with Nasdaq Listing Rule 5620(a).
• This compliance was achieved after the Company successfully held its 2025 Annual Meeting of Shareholders.
• Nasdaq has determined the compliance matter is now closed.

Important Information for Shareholders

The resolution of this compliance issue is significant for shareholders. Nasdaq Listing Rule 5620(a) requires listed companies to hold annual shareholder meetings. Failure to comply can lead to warnings, delisting proceedings, or reputational risk, all of which may negatively affect share value. The confirmation from Nasdaq that Telomir Pharmaceuticals is now compliant and that the matter is closed removes a major source of uncertainty for investors.

This update is potentially price-sensitive:

• It eliminates the risk of delisting from Nasdaq, ensuring continued liquidity and visibility for Telomir shares.
• It signals good corporate governance and responsiveness to regulatory requirements.
• It may encourage institutional investors who require Nasdaq-listed stocks for portfolio inclusion.

Additionally, Telomir Pharmaceuticals is identified as an Emerging Growth Company under SEC rules. This status allows the company to take advantage of reduced regulatory requirements, which can positively impact operational flexibility and cost structure. However, the company has not elected to use the extended transition period for complying with new or revised financial accounting standards, meaning it will adopt changes in accounting standards in line with other public companies. This may affect future reporting and transparency but is generally viewed positively by investors seeking more timely financial information.

Other Regulatory and Disclosure Details

• Telomir Pharmaceuticals, Inc. is incorporated in Florida and headquartered in Miami.
• The company’s common stock, trading under the ticker symbol TELO, is registered on the Nasdaq Stock Market LLC.
• No amendments to previously filed or accepted submissions were reported in this 8-K filing.
• There were no disclosures regarding written communications, soliciting materials, or pre-commencement tender offer communications, indicating no further regulatory actions or corporate events disclosed in this filing.

Potential Impact on Share Price

Resolution of Nasdaq compliance typically has a favorable effect on share price due to the removal of delisting risk and enhanced investor confidence. Investors should monitor trading activity following this announcement, as renewed confidence may attract new buyers or prompt short covering.

The confirmation of Telomir Pharmaceuticals’ compliance status, especially as an emerging growth company with no extended transition period for accounting standards, may also attract institutional interest and improve perceptions among analysts and retail investors.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Readers should perform their own due diligence and consult with financial advisors before making investment decisions. The information is based solely on the company’s SEC filings and may not include all material developments or risks.